Sesen Bio, Inc.
NASDAQ: SESN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas R. Cannell D.V.M.
- Employees
- 17
- Headquarters
- Cambridge, United States
- IPO year
- 2014
- Market cap
- $128.0M
- Website
- https://sesenbio.com
Loading SESN…
Loading profile data…Frequently asked questions about SESN
What does Sesen Bio, Inc. (SESN) do?
Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing...
Where does SESN trade?
Sesen Bio, Inc. (SESN) trades on the NASDAQ Capital Market.
What sector is SESN in?
Sesen Bio, Inc. (SESN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sesen Bio, Inc.?
Thomas R. Cannell D.V.M. is the chief executive officer of Sesen Bio, Inc. (SESN).
Where is Sesen Bio, Inc. headquartered?
Sesen Bio, Inc. is headquartered in United States.
Does SESN pay a dividend?
Sesen Bio, Inc. (SESN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SESN go public?
Sesen Bio, Inc. (SESN) completed its initial public offering in 2014.